By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...

Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D Maze also hopes to use the IPO to boost its Compass platform, which uses human genetic variation ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...